Biocon Biologics Bribery Case: CBI Moves HC Challenging Lower Court Verdict

The CBI approached the Delhi High Court on Tuesday challenging a lower court order denying it the custody of those arrested in the CDSCO bribery scandal allegedly involving a senior executive of Biocon Biologics, officials said.

The Delhi High Court has issued notices to the parties concerned and will hear the case on July 2, they said.

The CBI could not question the accused arrested by it even after six days, officials said and expressed apprehension that the delay might impede the investigation.

A special court here had sent all the five accused, including a joint drug controller at the Central Drugs Standard Control Organisation (CDSCO), to judicial custody after they were arrested for alleged bribery of Rs four lakh to waive phase-3 clinical trial of 'Insulin Aspart' injection of Biocon Biologics to manage Type 1 and Type 2 diabetes.

The CBI request seeking their police remand for custodial interrogation was denied twice by the special court which sent them to judicial custody.

Sources said CBI officials were disappointed that the court rejected their application for custody twice as immediate questioning after arrest in a trap case is of extreme importance for the agency so the accused do not get a chance to develop an alibi in their defence.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor